Over the last few years, BRAF has received considerable attention as a result of the success of targeted malignant melanoma therapy [25], and encouraging preliminary results have emerged from exploratory studies of the use of BRAF inhibitors in patients with BRAF-mutated MM [7, 9]. Here, BRAF is linked to melanoma.